Efficacy and Safety of the Use of Pulmonary Arterial Hypertension Pharmacotherapy in Patients with Pulmonary Hypertension Secondary to Left Heart Disease: A Systematic Review

Abstract

Pulmonary hypertension (PH) is often caused by left heart disease (LHD) such as heart failure (HF) or valvular heart disease. Historically, few randomized controlled trials have evaluated the off‐label use of medications for treating pulmonary arterial hypertension (PAH) in patients with PH‐LHD. However, multiple randomized controlled trials have been published over the last decade that investigated their use in patients with PH‐LHD. In addition, recent updates in the classification and definitions of PH have led to an improved recognition of PH‐LHD phenotypes, notably combined post‐capillary and pre‐capillary PH and isolated post‐capillary PH. In this systematic review, we show that PAH medications should not be recommended in two distinct HF populations: patients with HF without definitive PH diagnosis and patients with isolated post‐capillary PH due to HF. In addition, the use of bosentan or macitentan is not recommended in patients with combined post‐capillary and pre‐capillary PH due to HF, but sildenafil may be considered to improve pulmonary hemodynamics and exercise capacity in patients with combined post‐capillary and pre‐capillary PH due to HF. Riociguat 2 mg 3 times daily may also be considered to improve pulmonary hemodynamics in patients with combined post‐capillary and pre‐capillary PH due to heart failure with reduced ejection fraction but not heart failure with preserved ejection fraction. The postoperative use of sildenafil in the setting of PH after valvular heart disease intervention was evaluated. Limited clinical data and safety concern warrants caution with the postoperative use of sildenafil in patients with PH due to valvular heart disease. Despite recent advances in the understanding of PAH medications for patients with PH‐LHD, uncertainty remains about their utility in distinct subgroups. Nonetheless, PAH pharmacotherapy should generally be avoided for most patients with PH‐LHD.